

Comment on Trotman et al, page 2027, and Tam et al, page 2038

The race to stymie BTK: zanu zings

Prashant Kapoor¹ and Steven P. Treon² | ¹Mayo Clinic; ²Dana-Farber Cancer Institute

This issue of *Blood* presents a tour de force: Trotman and colleagues¹ report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.² to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88^{L256P} mutant Waldenström macroglobulinemia (WM). These companion articles on zanubrutinib will arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.

The approval in 2015 of ibrutinib, the first in-class BTK inhibitor for WM, was a watershed moment that followed, in short order, the discovery of a highly prevalent mutation in MYD88 in patients with WM.³ The understanding that mutated MYD88 triggers prosurvival signaling through BTK provided the rationale for investigating BTK inhibitors.⁴⁻⁶ Like ibrutinib, zanubrutinib irreversibly attaches to BTK,⁷ permanently shutting off its signaling capability (see figure). However, zanubrutinib may offer reduced off-target kinase inhibition, potentially improving tolerability.

Trotman et al evaluated zanubrutinib administered at 2 different doses (160 mg twice daily and 320 mg once daily) until progression, through a phase 1/2 trial (BGB3111-Au003) involving treatment-naïve patients (n = 24) and patients with relapsed/refractory WM (n = 53). The overall response rate was 96%, with a respectable subset achieving at least a very good partial response (VGPR). Notably, VGPR rates improved over time, from ~21% at 6 months to ~44% at 2 years. Ten patients discontinued zanubrutinib because of treatment-emergent toxicities. The twice-daily dosing schedule that resulted in more sustained BTK inhibition was selected to move forward.


These promising data provided the impetus for the international, phase 3 ASPEN trial through which Tam and colleagues sought to leverage the deeper responses induced by zanubrutinib. Demonstrating the superiority of the magnitude of response over ibrutinib, a standard of care

for WM, appeared to be a low-hanging fruit. With a primary endpoint that was somewhat unconventional for a phase 3 study and a robust international partnership, the ASPEN study had the trappings of a trial designed to facilitate brisk drug development in a rare malignancy for which differences in the progression-free survival (PFS), and more so, overall survival (OS), can take a long time to emerge. The primary endpoint was the proportion of patients achieving at least a VGPR as the best response, as assessed by an independent review committee at 12 months after the last patient's enrollment. With 1:1 randomization, ASPEN expeditiously accrued 199 evaluable WM (treatment naïve, n = 37; relapsed/refractory, n = 162) patients. Although complete response (CR) remained elusive (despite administration of drugs in both arms until progression), 28% and 19% achieved VGPR with zanubrutinib and ibrutinib, respectively (P = .09). Major response rates were strikingly similar (77% vs 78%), as were the 18-month PFS rates (84% and 85%) during the short follow-up. Barring grade 3 neutropenia, the toxicity-profile comparisons favored zanubrutinib over ibrutinib, also reflected by a lower discontinuation rate for zanubrutinib.

The ASPEN investigators had set a lofty goal of demonstrating at least a 20% improvement in VGPR/CR rates (35% with zanubrutinib vs 15% with ibrutinib). The justification for keeping VGPR/CR as a primary endpoint was ostensibly the feasibility of early analysis, with rapid attainment of responses and curtailment of the sample size in an uncommon

indolent malignancy for which the subjects would have otherwise needed protracted follow-up. Although the high VGPR rates observed with zanubrutinib in the BGB3111-Au-003 trial were noteworthy, it is not known whether the VGPR/CR rates are valid surrogate efficacy endpoints in WM. The magnitude of response, a time-dependent variable, is known to improve with continuous as well as fixed-duration therapy in WM. In the pivotal trial involving ibrutinib, the VGPR rates improved substantially from 15% to 29%, with longer follow-up.^{6,8} In ASPEN a numerically higher proportion of patients achieved VGPR with zanubrutinib, but the issue at heart is the real-world consequence of this finding. There are currently no prospective data on the use of BTK inhibitors to suggest that attainment of VGPR or deeper responses translates into substantive improvement in clinically meaningful endpoints of PFS and OS. Moreover, the 12-month PFS landmark analysis by best response in BGB3111-Au-003 demonstrably failed to correlate deep response with prolonged PFS. In ASPEN, the control arm performed as expected, mirroring the results of the pivotal trial and reinforcing ibrutinib's tenacity.^{6,9} Zanubrutinib performed somewhat below the ambitious expectations built upon the BGB3111-Au-003 data, underscoring the value of conducting phase 3 trials and longer follow-up. In addition, it brought into question excessive reliance on response rate and depth (known to be influenced by the CXCR4 mutation status of patients receiving BTK-targeted therapies)¹⁰ as the primary endpoint. Still, a sustained IgM reduction, as was demonstrated in favor of zanubrutinib, may be clinically pertinent, as WM-related morbidity, including peripheral neuropathy, cryoglobulinemia, cold agglutininemia, coexisting A(H)L amyloidosis, and hyperviscosity is driven by the monoclonal IgM protein.¹¹

The key findings of these 2 studies undeniably pull back the curtain on the uniqueness of WM, an IgM lymphoplasmacytic lymphoma,¹¹ with a near-ubiquitous presence of clonal mutated MYD88 molecular signature and subclonal CXCR4 mutations, encountered in 30% to 40% cases.^{12,13} Both genetic alterations are intricately linked, but have opposing effects on the efficacy of BTK-targeting agents: mutated MYD88 confers sensitivity, whereas CXCR4 mutations confer resistance. An important limitation for ASPEN was the low (9%) detection rate for CXCR4 mutations by Sanger sequencing,



Prosurvival signaling triggered by mutated MYD88 in WM and its interaction with BTK. BTK, a protein that is uniquely positioned in the B-cell receptor (BCR) signal transduction pathway, upon phosphorylation, interacts with myeloid differentiation primary response protein (MYD88), a Toll-like receptor (TLR) signaling protein, leading to an adaptive immune response, with IgM formation. BTK inhibition reduces MYD88-BTK complexing, with resultant downregulation of NF-κB and apoptosis of WM cells. Both ibrutinib and zanubrutinib irreversibly attach via covalent bonding to Cys481 residue within the BTK pocket, permanently shutting off its signaling capability by disrupting ATP binding. In addition, both ibrutinib and zanubrutinib target HCK, a SRC family member responsible for activating BTK in response to mutated MYD88. Two other irreversible BTK inhibitors, acalabrutinib and tirabrutinib, have demonstrated efficacy in WM. In addition, reversible BTK inhibitors, including vecabrutinib, LOXO-305, and ARQ 531, which can bind noncovalently to BTK, are under evaluation, given their potential to dually inhibit wild-type BTK and Cys481S-mutated BTK. Ulocuplumab, a monoclonal antibody against CXCR4 chemokine receptor 4 (CXCR4) and mavorixafor, a CXCR4 allosteric inhibitor, are being evaluated in partnership with ibrutinib, to overcome CXCR4-mediated resistance.

a stratification variable in the cohort. This issue was mitigated, in part, with a post hoc analysis, using the more sensitive next-generation sequencing, which increased the detection rate to 28%. More importantly, it unearthed an inequality in the distribution of patients with CXCR4 mutations across the 2 arms, favoring the ibrutinib arm (34% with zanubrutinib vs 22% with ibrutinib), a potential explanation for zanubrutinib narrowly missing the primary endpoint target. Fewer VGPRs were observed in both ibrutinib- and zanubrutinib-treated patients with mutated CXCR4 in comparison with those with wild-type CXCR4.

Although, both drugs demonstrated toxicities attributable to continuous inhibition of kinases, the stark differences in the intensities of adverse effects were exposed with the randomized controlled design of

ASPEN.² Because both were oral agents, an easily adoptable double-blind design, instead of the open-label study, could have reduced biases. Nonetheless, the well-recognized and oft-dreaded cumulative cardiovascular complications of atrial fibrillation (2% vs 15%) and grade 3 hypertension (6% vs 11%) were conspicuously lower with zanubrutinib. Similarly, the rates of diarrhea, muscle spasms, edema, and contusion favored zanubrutinib. However, grade 3 neutropenia (20% vs 8%), occurred more frequently with zanubrutinib, necessitating greater use of granulocyte colony-stimulating factor (47% vs 31%). Whether the profound neutropenia observed with zanubrutinib will pose challenges to partnering it with other agents remains to be seen.

Although the ASPEN study did not meet its primary endpoint, both ASPEN and BGB3111-Au-003 are highly instructive

trials, particularly when their findings are put into clinical context. The investigators should be commended for their valuable contribution. In hindsight, should ASPEN trialists have adopted a noninferiority design (with PFS as the primary endpoint), particularly when it is not necessarily the greater degree of BTK inhibition, but the reduced off-target effects (as exemplified by more favorable toxicity-profile and quality-of-life assessments) that is more likely to strike a chord with patients and practicing hematologists alike? Or will once-a-day convenience and longer clinical experience with ibrutinib drive clinical decision making? Regardless, for the pragmatist WM community, zanubrutinib, and will likely become an important treatment option for patients with WM.

Conflict-of-interest disclosure: P.K. has received research funding and has been a consultant to AbbVie, GlaxoSmithKline, Sanofi, and Takeda; has been a consultant to Cellectar, Karyopharm, and Pharmacyclics; and has received research funding from Amgen. S.P.T. has received research funding and has been a consultant to Pharmacyclics, X4 and BMS; has been a consultant to Janssen and Beigene; and has received research funding from Eli Lilly. ■

REFERENCES

1. Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. *Blood*. 2020;136(18):2027-2037.
2. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN Study. *Blood*. 2020;136(18):2038-2050.
3. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. *N Engl J Med*. 2012;367(9):826-833.
4. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. *Lancet Haematol*. 2020;7(2):e112-e121.
5. Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia [published online ahead of print 8 July 2020]. *Cancer Sci*. doi:10.1111/cas.14561.
6. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. *N Engl J Med*. 2015;372(15):1430-1440.
7. Zanwar S, Abeykoon JP, Kapoor P. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. *Curr Hematol Malig Rep*. 2020;15(1):31-43.

8. Treon SP, Meid K, Gustine J, et al. Ibrutinib monotherapy produces long-term disease control in previously treated Waldenström's macroglobulinemia: Final report of the Pivotal trial (NCT01614821). *Hematol Oncol*. 2019;37:184-185.
9. Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinemia: practice patterns, toxicities and outcomes. *Br J Haematol*. 2020;188(3):394-403.
10. Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenström macroglobulinemia cells. *Br J Haematol*. 2015;168(5):701-707.
11. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and Management of Waldenström

Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol*. 2017;3(9):1257-1265.

12. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. *Blood*. 2014;123(11):1637-1646.
13. Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinemia. *Br J Haematol*. 2016;172(5):735-744.

DOI 10.1182/blood.2020008197

© 2020 by The American Society of Hematology

MYELOID NEOPLASIA

Comment on Gleitz et al, page 2051

CXCL4's "Gliful" subversion of BM in MPN

Sandeep Gurbuxani | University of Chicago

In this issue of *Blood*, Gleitz et al report on a critical role of CXCL4 in inducing bone marrow (BM) fibrosis and inflammation, 2 hallmark features of primary myelofibrosis (PMF).¹

Classic *BCR-ABL1*⁻ myeloproliferative neoplasms (MPNs) include PMF, polycythemia vera, and essential thrombocythemia, all of which are characterized by disease-initiating somatic mutations in *JAK2*, *CALR*, or *MPL* genes.² The mutations are mutually exclusive and converge to activate *MPL-JAK-STAT* signaling.³ However, despite the common apical molecular events, MPNs display variation in BM pathology, are associated with different risks of disease progression, and require management strategies targeting a unique set of morbidities associated with each subtype. Even as the mechanisms underlying the biological differences among different MPNs remain an area of active investigation, it has become clear that the mutant hematopoietic stem cells (HSCs) and their progeny exert cell extrinsic effects resulting in inflammation and BM fibrosis, which in turn, further contribute to disease progression.³ This is evidenced by the tight association of BM fibrosis with increased cytogenetic aberrations, greater number of disease-specific mutations, and mutations associated with adverse outcome.⁴

It is now well established that the target cell that acquires the MPN-initiating

mutation is an undifferentiated HSC with multilineage potential. By contrast, the identity of cells responsible for BM fibrosis has remained elusive until recently when *LepR*⁺ and *Gli1*⁺ mesenchymal stromal cells were identified as the progenitors of fibrosis that cause myofibroblasts in the BM.^{5,6} Once the identity of the cells contributing to BM fibrosis was uncovered, the next obvious question was unraveling the pathways involved in the cross-talk between the malignant hematopoietic cells and the fibrosis-causing stromal cells.

In their article, Gleitz et al leveraged in vitro coculture experiments as well as several models of fibrosis-associated MPNs to uncover the interaction between hematopoietic cells carrying the MPN-defining mutations and *Gli1*⁺ myofibroblasts. It was previously shown that megakaryocytes contribute to BM fibrosis in a multitude of ways,⁷ and now the authors show that mutant HSCs overexpress multiple CXC chemokines, particularly CXCL4, and can reprogram *Gli1*⁺ stromal cells with as little as 72 hours of coculture by inducing upregulation of matrix-associated genes. In primary BM biopsies from patients with MPN,

CXCL4 overexpression seemed to precede reticulin fibrosis. Furthermore, in *JAK2*^{V617F} and *MPL*^{W515L} mouse models of MPN, CXCL4 knockdown improved anemia, leukocytosis, thrombocytosis, megakaryocytic atypia, and spleen size. In addition, CXCL4 knockdown prevented increased expression of profibrotic transforming growth factor β (TGF- β) in megakaryocytes and of inflammatory pathways such as nuclear factor kappa B (NF- κ B), tumor necrosis factor α (TNF- α), and TNF-related apoptosis-inducing ligand (TRAIL) in stromal cells in a thrombopoietin-induced model of BM fibrosis. However, even though there was reduced invasion of *Gli1*⁺ stromal cells into the marrow space, there was only modest reduction in BM fibrosis. More importantly, overexpression of CXCL4 alone was not sufficient to cause BM fibrosis, implicating additional pathways in the process.

CXCL4 was first implicated in the pathogenesis of PMF almost 4 decades ago.⁸ Gleitz and colleagues advance the field by uncovering the pathways downstream of CXCL4 and providing evidence that places CXCL4 upstream of many known inducers of inflammation and BM fibrosis. Moreover, the authors show that CXCL4 can positively amplify *JAK/STAT* signaling, a hallmark of all MPNs. CXCL4 therefore emerges as an attractive molecule for developing targeted therapy. However, even more fascinating is the observation that HSCs carrying MPN-associated mutations globally alter the gene expression profile of stromal cells in as little as 72 hours. Despite the fact that the data are derived from an ex vivo experiment, this observation raises several important questions. Is this reprogramming irreversible or does it become imprinted and independent of the mutant HSCs? If indeed the reprogramming of fibrosis-inducing mesenchymal stromal cells can be induced early by mutant HSCs, this is likely to happen long before clinical presentation of the disease. Finally, if confirmed, this study has profound implications on how we manage our expectations for response to even the most targeted and fibrosis-reversing therapy in PMF. Surely, a reprogrammed stromal cell is unlikely to reverse its phenotype through targeting of 1 specific pathway. Although this hypothesis is nihilistic, it might explain only partial reversal of BM fibrosis seen in previous